Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole vs ABLC for Prevention of Invasive Fungal Infections in Hematologic Malignancies
NCT00750737Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2008
- Primary completion
- Jun 2012
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in invasive fungal infection (IFI) comparing Posaconazole with Amphotericin B Lipid Complex (ABLC) (2 arms). Primary endpoint: Incidence of Invasive Fungal Infection. Started Jun 2008; status: completed.
02
Drugs
amphotericin B lipid complexposaconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT00750737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00750737.